Hcv polymerase inhibitors

Abstract

and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

1 . A compound represented by formula I: 
       
         
           
           
               
               
           
         
         wherein: 
         B is a nucleobase selected from the groups (a) to (d): 
       
       
         
           
           
               
               
           
         
         wherein Y is N or C(R 19 ); 
         R 1  is group (vi): 
       
       
         
           
           
               
               
           
         
         R 2  is H, C(═O)R 30 , C(═O)CHR 31 NH 2 , CR 32 R 32′ OC(═O)CHR 33 NH 2  or CR 32 R 32′ OC(═O)R 30    
         R 4 , R 5 , R 7  and R 8  are each independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, halo, OR 18 , SR 18  or N(R 18 ) 2 ; 
         R 6 , R 9 , R 10  and R 11  are each independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, halo, OR 18 , SR 18 , N(R 18 ) 2 , NHC(O)OR 18 , NHC(O)N(R 18 ) 2 , CN, NO 2 , C(O)R 8 , C(O)OR 18 , C(O)N(R 18 ) 2  and NHC(O)R 18 , wherein said C 2 -C 6 alkenyl group and said C 2 -C 6 alkynyl group can be optionally substituted with halo or C 3 -C 5 cycloalkyl; 
         R 13  is H or (C 1 -C 6 alkylene)-T-R 21 ; 
         each R 17  and R 17′  is independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, phenyl and benzyl; or both R 17  and R 17  together with the nitrogen atom to which they are attached form a 3-7 membered heterocyclic or a 5-6 membered heteroaryl ring which rings are optionally substituted with one or two groups independently selected from C 1 -C 3 alkyl, halo, C 1 -C 3 haloalkyl, amino, C 1 -C 3 alkylamino, (C 1 -C 3 alkyl) 2 amino; 
         each R 18  is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or C 3 -C 7 cycloalkyl; 
         R 19  is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, halo, OR 18  or N(R 18 ) 2 ; 
         each R 20  is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 hydroxyalkyl or C 3 -C 7 cycloalkylC-C 3 alkyl; 
         each R 30  is independently selected from C-C 6 alkyl and C-C 6 alkoxy; 
         each R 31  is independently selected from H, C-C 6 alkyl, C 3 -C 7 cycloalkyl, and benzyl; 
         each R 32  and R 32′  is independently selected from H and C 1 -C 3 alkyl; 
         each R 33  is independently selected from H and C-C 6 alkyl; 
         U is O or S; 
         each T is independently —S—, —O—, —SC(O)—, —C(O)S—, —SC(S)—, —C(S)S—, —OC(O)—, —C(O)O— and —OC(O)O—; 
         or a pharmaceutically acceptable salt and/or solvate thereof. 
       
     
     
         2 . The compound according to  claim 1 , wherein B is the group (a′): 
       
         
           
           
               
               
           
         
         wherein 
         R 5  is H or F, and R 6  is N(R 18 ) 2  or NHCOC-C 6 alkyl. 
       
     
     
         3 . The compound according to  claim 2 , wherein R 6  is NH 2 . 
     
     
         4 . The compound according to  claim 1 , wherein B is the group (b′): 
       
         
           
           
               
               
           
         
         wherein R 8  is H or F. 
       
     
     
         5 . The compound according to  claim 4 , wherein R 8  is H. 
     
     
         6 . The compound according to  claim 1 , wherein B is the group (c′): 
       
         
           
           
               
               
           
         
         wherein R 9  is OH or C 1 -C 6 alkoxy, and R 10  is NH 2  or NHCOC-C 6 alkyl. 
       
     
     
         7 .- 15 . (canceled) 
     
     
         16 . The compound according to  claim 1 , wherein R 2  is H. 
     
     
         17 . The compound according to  claim 1 , wherein R 1  is H. 
     
     
         18 .- 19 . (canceled ) 
     
     
         20 . A pharmaceutical composition comprising a compound according to  claim 1 , in association with a pharmaceutically acceptable adjuvant, diluent or carrier. 
     
     
         21 . A pharmaceutical composition comprising a compound according to  claim 1 , further comprising one or more additional other antiviral agent(s). 
     
     
         22 . A method for the treatment of hepatitis C virus infection comprising the administration of a compound according to  claim 1 . 
     
     
         23 . (canceled) 
     
     
         24 . The compound according to  claim 1 , wherein U is O.